SCHEMBL1308577

SCHEMBL1308577

O=C(Cl)COc1cccc(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.62
FKBP1A P62942 1/20 0.56
MAOB P27338 2/20 0.54
AOC3 Q16853 1/20 0.54
RXRA P19793 1/20 0.54
RXRB P28702 1/20 0.54
RXRG P48443 1/20 0.54
POLB P06746 1/20 0.54
KDM4E B2RXH2 2/20 0.53
GAA P10253 2/20 0.52
NOTUM Q6P988 2/20 0.52
TP53 P04637 1/20 0.52
ALOX12 P18054 1/20 0.52
ALDH1A1 P00352 2/20 0.50
LMNA P02545 1/20 0.50
PPARG P37231 2/20 0.49
PPARD Q03181 2/20 0.49
FFAR1 O14842 1/20 0.49
NR4A2 P43354 1/20 0.49
ENPP2 Q13822 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590819 1.00 WDR5 (0.62) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL4362709 0.88 LMNA (0.56) WDR5KDM4EGAAALDH1A1LMNA
SCHEMBL29447016 0.85 LMNA (0.64) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL523934 0.85 LMNA (0.64) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL11280610 0.84 WDR5 (0.60) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL9205686 0.84 WDR5 (0.65) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL9205693 0.84 WDR5 (0.70) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL11096716 0.83 WDR5 (0.55) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL10655453 0.81 WDR5 (0.57) WDR5FKBP1AMAOBAOC3RXRA
SCHEMBL10655455 0.81 WDR5 (0.57) WDR5FKBP1AMAOBAOC3RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118206525-A Aromatic ring [ d ] thiazepine ketone compound and preparation method thereof 北京化工大学 2024-06-18 CN disclosed
CN-109456324-B Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2022-04-22 CN disclosed
US-11028070-B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2021-06-08 US disclosed
US-20200262816-A1 ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2020-08-20 US disclosed
US-10689364-B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2020-06-23 US disclosed
EP-3024826-B1 NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2018-11-14 EP disclosed
US-20180002313-A1 ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2018-01-04 US disclosed
US-9809574-B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-11-07 US disclosed
US-9540332-B2 Benzimidazole derivatives as selective blockers of persistent sodium current ALLERGAN, INC. (US) 2017-01-10 US disclosed
US-9540332-B2 Benzimidazole derivatives as selective blockers of persistent sodium current ALLERGAN, INC. (US) 2017-01-10 US disclosed
WO-2007044724-A2 AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 EXELIXIS, INC. (US) 2007-04-19 WO disclosed
WO-2007028022-A2 NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2007-03-08 WO disclosed
EP-1747191-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES WITH A CHAIN EXTENSION Grünenthal GmbH (DE) 2007-01-31 EP disclosed
WO-2005110975-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES WITH A CHAIN EXTENSION Grünenthal GmbH (DE) 2005-11-24 WO disclosed
EP-0207690-B1 N-SUBSTITUTED GLUTAMIC ACID DERIVATIVE AND PROCESS FOR PRODUCTION AND USE THEREOF SUNTORY LIMITED (JP) 1989-12-20 EP disclosed
US-4701210-A HERBICIDES SUNTORY LIMITED (JP) 1987-10-20 US disclosed
EP-0207690-A1 N-Substituted glutamic acid derivative and process for production and use thereof SUNTORY LIMITED (JP) 1987-01-07 EP disclosed
US-4005074-A Process for cleaving an imido side chain from penicillins and cephalosporins ELI LILLY AND COMPANY (US) 1977-01-25 US disclosed
US-4001239-A CEPHALOSPORIN CLEAVAGE PROCESS ELI LILLY AND COMPANY (US) 1977-01-04 US disclosed
US-3994888-A Cephalosporin cleavage process ELI LILLY AND COMPANY (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002313-A1 ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BAX, CASP7, CASP3 WDR5 3127/4885FKBP1A 1507/4885MAOB 2432/4885
US-20200262816-A1 ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BAX, RECQL, CASP7 WDR5 3048/4885FKBP1A 1502/4885MAOB 2446/4885
US-10689364-B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them BAX, CASP7, CASP3 WDR5 3127/4885FKBP1A 1507/4885MAOB 2432/4885
US-11028070-B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them BAX, RECQL, CASP7 WDR5 3048/4885FKBP1A 1502/4885MAOB 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.